Lake Street raised the firm’s price target on Coya Therapeutics (COYA) to $17 from $16 and keeps a Buy rating on the shares after the company released preclinical in vivo neuroinflammation data for COYA-303 consistent with earlier in vitro preclinical results released by Coya.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics announces results from COYA 303 in vivo animal study
- Coya Therapeutics’ Promising ALS Study: A Potential Game-Changer?
- Coya Therapeutics Announces Public Offering of Shares
- Coya Therapeutics 3.64M Spot Secondary priced at $5.50
- Coya Therapeutics announces common stock offering, no amount given